

Announcement No. 02/2015
19 February 2015

Coloplast A/S
Holtedam 1
3050 Humlebæk
Denmark
Tel: +45 4911 1111
www.coloplast.com
CVR-nr. 69749917

Coloplast initiates the second part of the DKK 1bn share buy-back programme

Coloplast A/S is initiating the second part of the share buy-back programme totalling up to DKK 1bn, cf. announcement no. 2/2014 of 26 February 2014. The second part of the programme of DKK 500 million will take place in the period from 23 February 2015 to 24 August 2015. The first part of the programme, amounting to DKK 500 million, was executed in the 2013/14 fiscal year.

The share buy-back programme is being launched within the scope of the existing authority granted by the shareholders at the Annual General Meeting on 5 December 2013 for the repurchase of up to 10% of the company's share capital.

The buy-back programme has been structured to comply with the rules of Commission Regulation No. 2273/2003 of 22 December 2003, which provides for a safe harbour against a violation by the company of market abuse legislation in connection with the buy-back.

Coloplast A/S has entered into an arrangement with UBS under which the company has instructed UBS to repurchase on its behalf the company's B shares in the second part of the buy-back programme for a total consideration of DKK 500 million. UBS will make its trading decisions in relation to the purchases of the shares independently of, and without influence by, the company.

Subject to compliance with applicable laws and regulations, Coloplast A/S is entitled to stop the repurchase during the life of the buy-back programme. If the company decides to stop the repurchase, such a decision will be disclosed to the public by announcement to NASDAQ Copenhagen. Subsequently, UBS will no longer be instructed to purchase shares in Coloplast A/S on behalf of the company.

The programme is subject to the following main terms:

- The repurchase period will commence on 23 February 2015 and is expected to end no later than 24 August 2015.
- The total number of B shares to be repurchased will not be higher than a number of shares with a total net purchase price of DKK 500 million. Based on the current share price the approximate number of B shares expected to be acquired under the programme is 991,080 B shares equivalent to 0.5% of the share capital of Coloplast A/S.
- The number of shares to be repurchased each trading day is limited to 25% of the average volume of shares traded on NASDAQ Copenhagen during the preceding 20 exchange business days.
- The price paid by UBS for each share purchased for the account of the company will not exceed the higher of the following two prices: (1) the price of the last independent

trade and (2) the highest current independent bid on NASDAQ Copenhagen.

- The total consideration paid for shares acquired by the company under the programme (including any incentive fee payable by the company to UBS or vice-versa) will in any event not exceed DKK 500 million.
- For the duration of the repurchase period, UBS may be undertaking transactions in shares (which may include sales as well as purchases).
- This buy-back programme is made pursuant to the authorisation granted by the shareholders at the annual general meeting on 5 December 2013. The repurchased shares will either be annulled subject to separate approval by the general meeting or applied to cover obligations under employee share schemes.

Details of transactions executed under the buy-back programme will be publicly disclosed no later than by the end of the seventh trading day on www.coloplast.com during the repurchase period.

Prior to the launch of the share buy-back programme Coloplast A/S holds 8,495,848 B shares, equal to 3.9% of the company's share capital.

Lars Rasmussen
President and CEO

For further information, please contact

Investors and analysts

Ian S.E. Christensen
Vice President, Investor Relations
Tel. +45 4911 1800/+45 4911 1301
Email: dkisec@coloplast.com

Ellen Bjurgert
Investor Relations Manager
Tel. +45 4911 1800 / +45 4911 3376
E-mail: dkebj@coloplast.com

Press and the media

Simon Mehl Augustesen
Media Relations Manager
Tlf. 4911 3488
Email: dksia@coloplast.com

This announcement is available in a Danish and an English-language version.
In the event of discrepancies, the Danish version shall prevail.

Coloplast develops products and services that make life easier for people with very personal and private medical conditions. Working closely with the people who use our products, we create solutions that are sensitive to their special needs. We call this intimate healthcare.

Our business includes ostomy care, urology and continence care and wound and skin care. We operate globally and employ more than 9,000 people.

The Coloplast logo is a registered trademark of Coloplast A/S. © 2015-02 All rights reserved Coloplast A/S, 3050 Humlebæk, Denmark.